---
schema_version: "secwatch.filing_event.v1"
accession: "0001213037-26-000013"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2026-05-14T20:15:18+00:00"
generated_at: "2026-05-14T20:18:14.046261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology reports Q1 cash $46.1M, FDA aligns on Phase 3 design for onvansertib

## Summary
- Cash and investments $46.1M at Q1 end; net cash used $12.3M, runway into Q1 2027.
- Completed End-of-Phase 2 FDA meeting; selected 30 mg onvansertib + FOLFIRI/bev for Phase 3.
- Phase 2 CRDF-004: 30 mg arm ORR 72.2% vs SoC 43.2%; PFS HR 0.38 vs FOLFIRI/bev.
- Appointed Mani Mohindru as permanent CEO, Josh Muntner as CFO, Ajay Aggarwal as COO.
- Updated onvansertib data to be presented at ASCO 2026 rapid oral presentation.

## SEC filing metadata
- accession: 0001213037-26-000013
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2026-05-14T20:15:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/0001213037-26-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/crdf-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213037-26-000013
- JSON: https://secwatch.observer/filing/0001213037-26-000013.json
- Plain text: https://secwatch.observer/filing/0001213037-26-000013.txt

## Key facts
- Earnings Releases
  Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 14, 2026, Cardiff Oncology, Inc. issued a press release announcing a business update and financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/0001213037-26-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.